Search - tctmd.com

Displaying 1 - 20 of 109

Sort: Relevancy | Date

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

L.A. McKeown

February 14, 2025

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

L.A. McKeown

February 01, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2024

Shelley Wood

July 31, 2024

News Daily News

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Michael O'Riordan

July 09, 2024

News Daily News

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

L.A. McKeown

April 18, 2024

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

Todd Neale

February 15, 2024

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

Todd Neale

February 02, 2024

News Daily News

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

Todd Neale

December 05, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

Advertisement

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

What’s Going to Be Hot at ACC 2025?

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 2025 Dispatch for the CV Team

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

CMS Announces Negotiated Medicare Prices for First 10 Drugs

TCTMD’s Top 10 Most Popular Stories for July 2024

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

TCTMD’s Top 10 Most Popular Stories for November 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content